Member Info for MrMilton

More buys today - some of the big buys- as commercial news is on the way and too cheap at the moment.

Price bottomed at 24p. Nice move already 8.8%. With the report coming -

5p paid now .

Vol. Sold 364,634
Sold Value £82.04k
Vol. Bought 299,503
Bought Value £67.39k

Only 64,000 extra sold - MM put it 11% down- it is trying to shake weak holders to sell their share. Lots of 50,000 share bought today - some one accumulating. As Eurofin’s report is coming soon.

Also only 500,000 sold by two directors - keep in Mind one of the director’s are still holding around 20%- which shows their confidence. This will move fast after Eurofins news , along with commercialisation news which are due in coming months.
Also CEO :Michael Laurier CEO said: "this is a very exciting and positive development for our global sales team to bring to the market as quickly as possible. So commercial news is coming soon as well.
Till then hold tight.

6p coming in short term with the news expecting over 10p

NXP002 - Inhaled therapy for Fibrotic Diseases

Nuformix's NXP002 programme remains the Group's priority and entails the development of an inhaled therapy, initially for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Also

Negotiations regarding the out-licensing of pan-Asian rights to the Company's NXP002 programme are progressing well, albeit at a slower pace than expected as a result of the COVID-19 situation. The Directors are pleased with progress to date and look forward to further positive discussions in the coming months- May news

News on the way. Over 6p soon

With the news expecting over 100p today

This will fly today over 16p

The contract is expected to deliver significant revenue for Venn Life Sciences ("Venn") over the next twelve months.
Excellent RNS -

Fibrosis news is imminent- this will fly over 8p after the clinical news-

Very positive RNS - with the new partnership . This should go beyond 30p

According to their previous RNS : The Company's Directors are currently in discussions with several companies in the healthcare sector that have expressed an interest in proceeding with a reverse takeover.

Very much hopeful for a RTO- particularly in COVID-19 situation.

Over 34% already

Serious buying going on!!!

Copied from Some one:

So much going on with DDDD. They're at the forefront of a whole new class of drugs which have almost limitless applications. The Company has six clinical studies in progress: * A Phase II clinical study of BLAUTIX(R) in Irritable Bowel Syndrome (IBS). * A Phase I/II study of MRx0518 in combination with KEYTRUDA(R) (pembrolizumab) in solid tumours. * A Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours. * A Phase I study of MRx0518 in patients with pancreatic cancer * A Phase I/II study of MRx-4DP0004 in asthma. * A Phase II study of MRx-4DP0004 in patients with COVID-19. Plus, Preclinical-stage programmes include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. Plus, The Company has a $1bn+ research collaboration and option to license agreement with MSD (the tradename of Merck & Co., Inc, Kenilworth, NJ USA), to discover and develop LBPs for vaccines. Plus they own the largest intellectual property estate in the microbiome sector (over 950 granted patents). Plus they own their own commercial scale production facilities::::::::

Jumped 32% already

New Contract worth £2.7M - Total contract is over £12m. Should be oevr 70P

Market Cap just over £4m -

Good move to put luke

They sold all -TR will come soon . As usually it takes couple of days time to come

Seller's out and funding will be sorted soon. Expecting a big rise tomorrow as well.